Long-Acting Lipoglycopeptides Can Interfere With Vancomycin Therapeutic Drug Monitoring.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.1975
Abstract: Oritavancin and dalbavancin are long-acting lipoglycopeptides with activity against susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. Though similar in structure to traditional glycopeptide antibiotics like vancomycin, these antibiotics have terminal half-lives greater than 10 days,… read more here.
Keywords: vancomycin; long acting; therapeutic drug; acting lipoglycopeptides ... See more keywords
Long-Acting Lipoglycopeptides for Gram-Positive Bacteremia at the End of Life to Facilitate Hospice Care: A Report of 3 Cases
Sign Up to like & getrecommendations! Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx277
Abstract: Abstract Administering and monitoring intravenous antimicrobials may cause discomfort in patients at the end of life and delay transition to hospice. We describe 3 patients with terminal cancer with methicillin-resistant Staphylococcus aureus, Streptococcus gallolyticus, and… read more here.
Keywords: facilitate; long acting; end life; hospice ... See more keywords
New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides
Sign Up to like & getrecommendations! Published in 2022 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.02614-20
Abstract: The long-acting lipoglycopeptides (LGPs) dalbavancin and oritavancin are semisynthetic antimicrobials with broad and potent activity against Gram-positive bacterial pathogens. While they are approved by the Food and Drug Administration for acute bacterial skin and soft… read more here.
Keywords: perspectives antimicrobial; long acting; acting lipoglycopeptides; potential role ... See more keywords